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Abstract 
 
Co-morbid chronic musculoskeletal pain (CMSP) and posttraumatic stress symptoms (PTSS) are 
frequent sequelae of motor vehicle collision (MVC), are associated with greater disability than either 
outcome alone, and are more prevalent in women vs men. In the current study we assessed for 
evidence that gene transcripts originating from the X chromosome (XCh) contribute to sex differences 
in vulnerability to CMSP/PTSS after MVC. Nested samples were drawn from a longitudinal study of 
African American individuals, and CMSP (0-10 Numeric Rating Scale) and PTSS (Impact of Events 
Scale, Revised) outcomes were assessed six months following MVC. Blood RNA were sequenced 
(n=101) and the relationship between XCh mRNA expression levels and co-morbid CMSP/PTSS 
outcomes was evaluated using logistic regression analyses. A disproportionate number of peritraumatic 
XCh mRNA predicting CMSP/PTSS in women were genes previously found to escape XCh inactivation 
(XCI) (11/40, z=-2.9, p=0.004). Secondary analyses assessing gene ontology relationships between 
these genes identified an enrichment in genes known to influence neuronal plasticity. Further, the 
relationship of expression of two critical regulators of XCI, XIST and YY1, was different in women 
developing CMSP/PTSS. Together, these data suggest that XCh genes that escape inactivation may 
contribute to sex differences in vulnerability to CMSP/PTSS after MVC. 
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Introduction 
 
 Exposure to traumatic events is common in life.1 In industrialized nations, motor vehicle collisions 
(MVCs) are one of the most common types of trauma1, with over 50 million MVCs occurring worldwide 
each year2. The great majority of individuals experiencing MVC do not have serious injury; in the US, 
more than 90% of individuals seen in the emergency department after MVC are discharged home after 
evaluation3. A substantial proportion of such individuals develop chronic musculoskeletal pain (CMSP)4-
6 and/or posttraumatic stress symptoms (PTSS)7-9. Some individuals develop both CMSP and PTSS 
(CMSP/PTSS); such individuals experience greater mental and physical disability than those with either 
outcome alone10-14, are are an important outcome group for further study15. 
 Most individuals who develop CMSP/PTSS following MVC are women.16-18 This fact is consistent 
with the marked increase in CMSP and PTSS burden experienced by women vs. men in other 
settings.19-25 Additionally, data from animal models suggest that there are sex differences in response 
to stress/priming events that lead to increased hyperalgesia and deficits in fear extinction26-30. Despite 
substantial sex differences, genetic/molecular mechanisms responsible for increased CMSP/PTSS 
vulnerability in women remain poorly understood. 
 One biological mechanism that may contribute to increased CMSP/PTSS vulnerability in women 
is altered expression of messenger RNA (mRNA) originating from the X chromosome (XCh). Women 
have two copies of the XCh (XX), while men have only one copy (XY). In women one copy of each XCh 
gene is silenced via a process termed XCh inactivation (XCI). Mechanisms important to XCh silencing 
include epigenetic/chromatin modification and the coating of one XCh by the long non-coding RNA 
(lncRNA), XIST31-34. The latter mechanism, XIST RNA coating, requires the YY1 protein to activate the 
XIST RNA and tether it to the XCh35. Interestingly, despite such inactivation mechanisms, 10-15% of 
XCh genes escape XCh inactivation (XCI) and are bi-allelically expressed36. XCh genes that escape 
XCI have been shown to play a pathogenic role in many diseases37-47. 
 Increasing evidence suggests that altered expression of mRNA originating from the XCh in 
general, and escape from XCI in particular, may be an important mechanism contributing to sex 
differences in CMSP/PTSS susceptibility. XIST RNA has been found to be dysregulated in women with 
CMSP/PTSS-related major affective disorders37,38, sex choromosome abnormalities contribute to a 
range of brain-health disorders48, XCI mechanisms have been implicated in nervous system 
development and function49, and in mice, YY1 expression is associated with inflammatory pain and 
stress-induced analgesia50. 
 In this study, we assessed for evidence that expression differences in mRNA originating from 
the XCh contribute to the increased incidence of CMSP/PTSS in women experiencing MVC. We 
hypothesized that altered expression of mRNA originating from the XCh would predict the development 
of co-morbid CMSP/PTSS in such women. In addition, we hypothesized that XCh genes known to 
escape from XCI would predict CMSP/PTSS development, and play an important role. In addition, we 
evaluated whether the peritraumatic expression of critical regulators of XCI, XIST and YY1, also predict 
CMSP/PTSS outcomes.  
  
Materials/Subjects and Methods  
 
Parent longitudinal cohort study of women and men experiencing MVC 
 
 This prospective longitudinal study enrolled African American individuals ≥ 18 and ≤ 65 years of 
age who presented within 24 hours of MVC to one of eleven emergency departments (EDs) in six 
states/districts (Michigan, Pennsylvania, Florida, Alabama, Massachusetts, and Washington D.C.) 
between July 2012 and July 2015. The study only enrolled African Americans because of the pressing 
need for pain studies that focus on such understudied, high risk groups.51-53 This study has been 
described in detail previously.54 In brief, individuals who did not have a fracture or other injury requiring 
hospital admission were screened for eligibility. Patients who were not alert and oriented were 
excluded, as were patients who did not self-identify as African American, pregnant patients, prisoners, 
patients unable to read and understand English, or patients taking opioids above a total daily dose of 
30 mg of oral morphine or equivalent. The study was approved by the institutional review boards of all 
participating hospitals. Each participant provided written informed consent before enrollment.  
 MVC-related pain intensity and distribution in the past week was assessed six months following 
MVC using the modified Regional Pain Scale.55 Overall pain intensity was evaluated via a 0 (no pain) 
to 10 (maximum possible pain) numeric rating scale (NRS).56 MVC-related PTSS was assessed six 
months following MVC using the Impact of Event Scale: Revised (IESR).57 This 22-item questionnaire 
assesses symptoms such as physical reactions, dreams, and reminders of the stressful event on a 
scale of 0-4. The questionnaire also includes assessments for avoidance, intrusion and hyperarousal 
subscales; total scores can range from 0-88. 
Sample selection and outcome definitions 
 
 To increase power, samples were not selected from the parent cohort study for analyses at 
random. Rather, individuals with relatively high levels and relatively low levels of pain and PTSS over 
time after MVC were selected from the overall cohort for gene expression analyses (more extreme 
phenotypes). In addition, only parent cohort participants who at the time of the emergency department 
visit reported little or no pain in the weeks prior to MVC were selected, and only participant samples 
with an RNA integrity score of 7 or greater were selected for sequncing. This selection occurred 
intermittently throughout the parent study by a single investigator (SDL), when samples were selected 
for gene expression analyses, and well prior to planning of these specific analyses. 
 Individuals with co-morbid CMSP/PTSS were defined based on previously validated cut-offs for 
moderate-severe pain (NRS ≥ 4) and PTSS (IES-R score ≥ 33).58 Individuals with co-morbid 
CMSP/PTSS were compared to controls (individuals reporting neither CMSP nor PTSS). The average 
NRS and IES-R scores of women who developed co-morbid CMSP/PTSS was 7.98 (SD 1.71) and 
59.33 (SD 15.79), respectively, while the NRS and IES-R scores of women who recovered was 0.71 
(SD 1.10) and 8.51 (SD 8.51), respectively. 
 
RNA collection and isolation from MVC study participants 
 
 Research assistants collected blood samples in the ED at the time of enrollment using PAXgene 
RNA tubes. Total RNA was isolated using the PAXgene blood miRNA kit (QIAGEN) and RNA was 
stored at -80˚C until use. RNA concentration and purity were measured using a NanoDrop One 
(Nanodrop Technologies, Wilmington, DE), and RNA integrity was measured using an Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA).  
 
Next Generation Sequencing and RNA read count normalization 
 
 Template libraries for total RNA sequencing were produced from 600ng total RNA using Ovation 
Human Blood RNA-Seq Library Systems kit (NuGen, San Carlos, CA) according to manufacturer’s 
specifications. Libraries were multiplexed in groups of six and sequenced on a HiSeq 2500 at the 
University of North Carolina at Chapel Hill High Throughput Sequencing Facility. Raw sequencing reads 
were aligned to the human hg19 genome assembly using STAR (version 2.4.2a).59 Expression levels 
of each transcript (n=20,353) were estimated via RSEM60 using University of California Santa Cruz 
(UCSC) known gene transcript and gene definitions. Raw RSEM read counts for all samples were 
normalized to the overall upper quartile61 before comparison and visualization. Consistent with study 
goals, only non-pseudoautosomal region (non-PAR) messenger RNA (mRNA) originating from the X 
chromosome (n=783) with mean read counts ≥ 10 (n=724) were included in analyses. As a quality 
control measure and verification of appropriate male/female categorization based on genetic attributes 
(vs. self-reported gender), median XIST RNA read counts were compared between women and men in 
this cohort: median XIST RNA read counts were 99,806 in women and 339 in men.  
 
Statistical analyses  
 
 Sample sociodemographic characteristics were summarized using standard descriptive 
statistics. Logistic regression analyses adjusted for ED study site, education level, and participant age 
were used to assess the relationship between XCh gene expression levels and co-morbid CMSP/PTSS 
6 months following MVC, and to derive β coefficients, Z-score, standard error and p-value significance. 
RNA expression levels were scaled using the ‘Scale’ function in R. For this exploratory study, a p-value 
significance threshold for each of the different hypotheses assessed was set at p < 0.05. Gene 
expression values meeting this threshold were used to generate a heatmap comparing relative 
expression levels of significant genes in women who develop CMSP/PTSS vs recovery following MVC. 
 To determine whether there was a statistically significant difference in proportions of genes from 
two different groups, a z score and p value were calculated by comparing the proportions between the 
two groups using a two-tailed significance test. 
 Competitive gene set analyses (CGSA) were performed using the limma package in 
R/Bioconductor, version 3.34.962. The Camera function was used to test whether specified sets of 
genes (e.g. EscapeSet) were more highly ranked in an ordered list of genes than would be expected 
by chance. While some CGSA methods (e.g., WilcoxGST) assume that each gene is conditionally 
independent of other genes, Camera adjusts for inter-gene correlation and is thus considered a more 
rigorous analysis for large sets of related genes63.  
 The relationship between XIST RNA expression levels and YY1 mRNA expression levels with 
CMSP or PTSS was assessed using bivariate analyses (Pearson Correlation) in stratified outcome 
groups (women who developed co-morbid CMSP/PTSS vs those who recovered). All statistical 
analyses were carried out using SPSS software v24.0, SAS software v9.4, or R Studio v3.3.3.  
 
Pathway analyses 
 
 The Ingenuity Pathway Analysis (IPA, Qiagen, 2018) software was used to assess functional 
relationships between XCh genes that predicted CMSP/PTSS, XCh genes known to escape XCI that 
predicted CMSP/PTSS (“EscapeSet”, n=9) and XChSet (n=31) separately. A core expression anlysis 
was done to assess the similar functionalities between genes in the context of curated Canonical 
pathways in the IPA library. Functional relationships identified using IPA were validated across three 
other freely-available pathway analysis tools available online: DAVID64,65, PANTHER66, and 
GATHER67. 
 
 
  
Results 
 
Study participants / Cohort 
 
 Study analyses were performed on a subsample of participants from a parent prospective 
observational study of African American (AA) women and men who presented to the ED for evaluation 
after MVC. This subsample was comprised of participants who were selected to have gene expression 
analyses performed on RNA blood samples obtained from them in the ED. Participants who reported 
little or no pain in the weeks prior to MVC and who had more extreme outcome phenotypes (little or no 
symptoms, or more substantial persistent symptoms) were selected for gene expression analyses. 
Samples with an RNA integrity score of 7 or greater were used in the present analyses. This method 
removed those with prior pain and enriched the study subsample for the outcome of interest (i.e., 25% 
of parent cohort (n=930) had co-morbid CMSP/PTSS six months following MVC, vs. 51% of the study 
subsample (n = 101)). The majority of these study subsample participants were between twenty and 
forty years of age and had not completed college; a little more than 60% were female (Table 1). The 
majority were drivers, and more than half reported severe damage to their vehicle (Table 1). 
Peritraumatic pain and distress were common in the cohort, and consistent with selection critieria, pain 
symptoms in the weeks prior to MVC were mild (Table 1). 
 
Associations between altered peritraumatic expression of XCh mRNA and CMSP/PTSS 
outcomes in women vs. men 
 
 In logistic regression analyses adjusted for participant age, education level, and enrollment study 
site, forty mRNA originating from the XCh were differentially expressed in the early aftermath of MVC 
among women who developed CMSP/PTSS (n=30) vs those who recovered (n=35) (p < 0.05; Figure 
1 and Table 2). Differences in expression of these RNA transcripts ranged from -4 to 4 fold at the 
individual level (Figure 1) and 0.64 to 1.58 fold at the group level (Table 2). These mRNAs clustered 
into two main groups, one group showing predominately increased expression of differentially 
expressed XCh mRNA in women who developed CMSP/PTSS (n=23 mRNA) and another group with 
predominately decreased expression in women who developed CMSP/PTSS (n=17 mRNA) (Figure 1). 
These RNA transcripts have been identified as having a variety of broad ranging functions such as 
regulation of transcription/translation (e.g. EIF1AX, EIF2S3), immune cell function (e.g. CD40LG, TLR8, 
SH2D1A), and cell communication/signaling (e.g. GPR174, GPRASP1) (Supplementary Table 1). In 
parallel logistic regression analyses conducted in men who developed CMSP/PTSS (n=21) vs those 
who recovered (n=15), twenty-five mRNA were differentially expressed; these mRNAs did not cluster 
into well-defined groups as they did in women (Supplementary Figure 1). Differences in expression 
of these RNA transcripts ranged from 0.58 to 15.71 fold at the group level (Supplementary Table 2). 
Similar analyses of CMSP/PTSS-associated XCh genes in men indicated that differentially expressed 
XCh mRNA were nearly entirely distinct from those identified in women (only RBBP7 and SEPT6 that 
were associated with CMSP/PTSS in both sexes). 
 
In women, but not in men, XCh gene transcripts that predict post-MVC co-morbid CMSP/PTSS 
are enriched in gene transcripts that have been shown previously to escape XCI 
 
 In women, 11/40 (28%) of XCh mRNA differentially expressed in those who subsequently 
developed CMSP/PTSS have been shown in previous literature to escape XCI68-71 (Figure 2). When 
compared to the total number of XCh genes shown in previous literature to escape XCI71 (93/783, 12%, 
Supplementary Table 3), the percentage of escape genes predicting CMSP/PTSS in women was 
much higher than would be expected due to chance (z = -2.9, p = 0.004, Figure 2A). In contrast, in 
men the twenty-five XCh mRNA differentially expressed in those who did vs. did not develop 
CMSP/PTSS were not enriched for genes that escape XCI (3/25, 12%; z = -0.0187, p = 0.984). 
 
The great majority of XCh gene transcripts found in previous literature to escape XCI and that 
were differentially expressed in the early aftermath of MVC among women developing 
CMSP/PTSS were differentially expressed in a direction consistent with escape from XCI 
 
 Consistent with the direction of effect that would be expected of escape gene transcripts, nine 
out of eleven XCh gene transcripts found in previous literature to escape XCI and that were differentially 
expressed in the early aftermath of MVC among women developing CMSP/PTSS were expressed at 
higher levels in women who developed CMSP/PTSS vs those who recovered. This set of nine genes 
was the focus of the following analyses and are herein referred to as “EscapeSet” genes. Consistent 
with the chromosomal location of most genes that escape XCI72, the majority of EscapeSet transcripts 
originate from the distal end of the short arm of the XCh (Figure 2B).  
 
EscapeSet gene transcripts demonstrated greater differential expression in women who 
developed CMSP/PTSS than both other differentially expressed XCh genes and other sets of 
genes 
 
 In competitive gene set analyses (CGSA) that further account for inter-gene correlation (Camera, 
Bioconductor/R), EscapeSet genes were more differentially expressed (in the direction of increased 
expression) in women who developed CMSP/PTSS vs those who recovered than the other 31 
differentially expressed XCh genes (the “XChSet”, p=0.004, Figure 2C). The EscapeSet was also more 
differentially expressed in women who developed CMSP/PTSS vs recovered in comparison to other 
randomly selected sets of nine genes from the XCh (Direction: up-regulated, p= 8.81x10-15, Figure 2C) 
and when compared to any other set of nine genes from the full transcriptome (Directoin: up-regulated, 
p =4.75x10-12, Figure 2C). 
 
EscapeSet pathway analyses indicate an enrichment for genes involved in protein translation 
 
 Shared relationships between EscapeSet genes were evaluated via pathway analysis (IPA 
software). An enrichment of the Eukaryotic Initiation Factor 2 (EIF2) Signaling/Protein Biosynthesis 
Pathway was identified (Canonical pathway enrichment function, p=9.9x10-5), a pathway which 
regulates translation in response to a range of stress-related signals73. Enrichment of this pathway was 
mainly driven by differential expression of escape genes EIF1AX, EIF2S3, and RPS4X, which have 
been shown to play a role in the regulation of transcription and translation. Additionally, using the 
Network analysis function in IPA, we found that EscapeSet genes are all connected to IL2 
regulation/function/signaling (Figure 2D). The association between EscapeSet genes and translational 
regulation was confirmed with additional pathway analysis software including GATHER (enrichment in 
protein biosynthesis (GO:0006412, Bayes Factor = 3, p value = 0.002)), PANTHER (translation 
initiation” (GO:0003743, >100 fold enrichment, p = 1.65x10-4)), and DAVID (enrichment in translational 
initiation (GO:0006413, p value = 1.8x10-3)). 
 
Expression levels of the non-coding RNA XIST and the transcription factor YY1 were 
differentially associated with each other and with CMSP/PTSS outcomes when comparing 
women who developed CMSP/PTSS vs women who recovered following MVC  
 
 Based on our results showing that women who develop CMSP/PTSS following MVC over-
express more genes that escape XCI than expected based on chance, we hypothesized that these at-
risk women would also exhibit further evidence of altered XCI. Therefore, we examined the relationship 
between the expression of two major regulators of XCI, XIST and YY1, and CMSP or PTSS outcomes 
in women who recovered and in women who developed co-morbid CMSP/PTSS following MVC. We 
first assessed a relationship between XIST RNA expression and PTSS severity and found that in 
women who recovered there was no statistically significant relationship (r = -0.113, p = 0.520, Figure 
3A). However, in women who developed co-morbid CMSP/PTSS, we found a negative relationship 
between XIST RNA and PTSS severity, with trend level statistical significance (r = -0.294, p = 0.114, 
Figure 3A).  Similar (though non-significant) relationships were observed when assessing the 
correlation between XIST RNA expression levels and CMSP severity in women (Supplementary 
Figure 2) but no such relationships were observed in men (Supplementary Figure 3A).  
 We next examined whether there was a relationship between YY1 mRNA expression and PTSS 
and found that in women who recovered, there was no statistically significant relationship (r = 0.187, p 
= 0.281, Figure 3A). However, in women who developed co-morbid CMSP/PTSS, we found a positive 
relationship between YY1 mRNA expression and PTSS severity, with trend level statistical significance 
(r = 0.351, p = 0.057, Figure 3A). The relationship between YY1 mRNA expression and CMSP severity 
in women was not as pronounced as was observed for PTSS severity (Supplementary Figure 2) and 
no statistically significant relationships were observed in men (Supplementary Figure 4). 
 To further extend these analyses, we examined whether there were different relationships 
between XIST RNA and YY1 RNA expression in women who recovered vs women who developed co-
morbid CMSP/PTSS following MVC. In women who recovered, we detected a negative correlation with 
trend level statistical significance (r = -0.315, p = 0.065, Figure 3B). In comparison, in women who 
developed co-morbid CMSP/PTSS, we detected a strong and highly significant negative correlation 
between these RNA molecules (r = -0.582, p = 0.0007, Figure 3B). In contrast, in men, we detected 
positive correlations between XIST and YY1 RNA expression levels in both outcome groups 
(Supplementary Figure 3B). 
 
Discussion 
 
 In the current study, we found that forty genes originating from the XCh were differentially 
expressed in the early aftermath of MVC among women who subsequently developed CMSP/PTSS vs 
those who recovered, and twenty five XCh genes were differentially expressed in men. Differentially 
expressed XCh genes in women demonstrated greater fold change than men, were nearly entirely 
distinct from men, clustered into two well-defined groups, and unlike men were greatly enriched for 
genes previously shown to escape XCI. In addition, the expression of XCh genes known to escape XCI 
appeared to be particularly dysregulated, as this subset of nine genes exhibited greater differential 
expression than any other nine gene set from the XCh or the full transcriptome. Importantly, consistent 
with potential escape from XCI, in women who developed CMSP/PTSS these genes exhibited 
increased expression. These results, together with data indicating that women who developed 
CMSP/PTSS following MVC exhibited altered relationships between XIST and YY1 RNA expression 
levels, provide evidence that support the hypothesis that genes that escape XCI might contribute to the 
increased vulnerability to CMSP/PTSS in women experiencing MVC. 
 Pathway analyses to look for clues regarding mechanisms through which differentially expressed 
XCh genes that escape XCI might contribute to increased CMSP/PTSS vulnerability in women 
implicated EIF2 signaling. The EIF2 pathway has been shown to be involved in the cellular response 
to diverse stressors73-75. More recently, the EIF2 pathway in neurons has also been shown to be 
involved in processes related to learning and neuroplasticity76-78; processes central to the alterations in 
central and peripheral nervous system function that mediate the development of CMSP and PTSS. 
Pathway analyses also indicated that differentially expressed XCh genes that escape XCI influence IL-
2 signaling/function. IL-2 has been implicated in the pathogenesis of both chronic pain79,80 and PTSS81-
84. Further studies evaluating the potential contribution of EIF2 and IL-2 signaling to sex differences in 
pain and PTSS outcomes after MVC and other stressors are warrented. 
 Our results demonstrating a negative correlation between XIST RNA expression levels and 
PTSS or CMSP severity in women who developed co-morbid CMSP/PTSS was interesting in light of 
our consistent results showing that genes known to escape from XCI predict CMSP/PTSS development 
in women following MVC. These data suggest that low levels of XIST RNA expression (and thus 
potentially less coating of the inactive XCh) may allow certain XCh RNA to escape XCI in women who 
go on to develop CMSP/PTSS. Of note, in addition to the amount of XIST RNA available to silence the 
XCh, available evidence suggest that regulation of intracellular location of XIST RNA may also be 
important. For instance, in an elegant study by Wang et al, women with systemic lupus erythematosus 
(SLE) exhibited dispersed localization of XIST in mature naïve lymphocytes, leading to gene escape 
from XCI in these cells85. This finding is of interest because our data our potentially consistent with the 
mechanism, and like CMSP/PTSS, SLE is a disorder that disproportionately affects women. Wang et 
al. also examined expression of the YY1 protein and its ability to recruit XIST to the inactive XCh, and 
showed that YY1 was important for XIST localization. Interestingly, we found that the relationship 
between YY1 and PTSS severity (but not CMSP severity) and the relationship between YY1 and XIST 
is more pronounced in women who developed CMSP/PTSS, indicating that the amount and the 
relationship between these RNA molecules might contribute to gene escape from XCI in these women. 
However, these results should be interpreted with caution as they are only correlative, and further 
mechanistic studies are needed. 
 The strengths of this study included our ability to obtain nested samples from a prospective study 
of trauma survivors with high follow-up rates, our ability to increase power via selection of more extreme 
phenotypes (reduced type II error), the quality of the RNA data used in the study, and our ability to look 
for evidence that genes that escape XCI contribute to sex differences in vulnerability to post-MVC 
CMSP/PTSS using multiple complementary approaches in both women and men (i.e., gene expression 
analyses, pathway analyses, XIST and YY1 RNA association analyses). However, several limitations 
should also be considered when interpreting our results. First, the main findings of the study have not 
been replicated in a second cohort of post-trauma survivors. This is an essential next step for future 
studies. Second, this study did not adjust for multiple hypothesis testing. This has the disadvantage of 
producing false positive associations (i.e. Type I error), but is optimal given the exploratory nature of 
the study and our relatively small sample size. Third, this work was performed in only African American 
individuals. Therefore, whether there are also ethnic differences in the association between XCh genes 
and CMSP/PTSS is not known. Fourth, we relied on previous studies for the identification of escape 
genes and did not assess escape status in our cohort. However, most of the escape genes identified 
as predictors of CMSP/PTSS have been shown across a number of studies to escape XCI71. Finally, 
we have not performed mechanistic studies to more fully explicate relationships between XIST and YY1 
RNA expression levels in women who develop CMSP/PTSS vs recover. Further studies are needed to 
replicate these findings and, if present, to better understand the underlying mechanisms driving these 
differences. 
 In conclusion, we report the first evidence suggesting that differential expression of genes 
originating from the X chromosome, including genes that escape X chromosome inactivation, may 
contribute to the increased vulnerability to co-morbid CMSP/PTSS in women vs. men experiencing 
MVC. The expression of expression of a set of XCh genes known to escape XCI appeared to be 
particularly dysregulated/influential; pathway analyses indicate that the affect of these genes may 
include influencing the EIF2 pathwway, which is involved in neuronal neuroplasticity. Further 
suggesting a role in CMSP/PTSS pathogenesis of X chromosome genes that escape inactivation, 
women who developed CMSP/PTSS following MVC exhibited altered relationships between XIST and 
YY1 RNA expression levels. Future studies are needed to further understand the potential role of X 
chromosome gene expression in general, and X chromosome genes that escape X chromosome 
inactivation in particular, in mediating sex differences in vulnerability to CMSP/PTSS after MVC. 
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Table 1. Participant characteristics  
Participants, n 101 
Female, n (%) 65 (64.4) 
Age, years, mean (SD) 31.4 (10.8) 
Education, n (%)  
     HS or less 44 (43.6) 
     Post-HS not college  4 (4) 
     Some college 34 (33.7) 
     College 15 (14.9) 
     Post-college 4 (4) 
Collision characteristics  
     Driver, n (%) 72 (71.3) 
     Severe vehicle damage, n (%) 58 (57.4) 
     Seatbelt worn, n (%) 86 (85.1) 
     Airbag deployed, n (%) 38 (37.6) 
Pain level prior to MVC (0-10 NRS), mean (SD) 1.0 (2.2) 
Overall pain in the ED (0-10 NRS), mean (SD) 6.9 (2.3) 
Peritraumatic distress level*, mean (SD) 24.8 (12.2) 
*distress measured with the peritraumatic distress inventory 
	
	 	
 
Figure 1. Heatmap illustrating X chromosome genes that are differentially expressed in women who recover vs 
develop co-morbid CMSP/PTSS six months following motor vehicle collision (MVC) (n=65). Each column 
represents a female participant from the study, with individuals who recovered on the left (light gray bar) and 
individuals who developed CMSP/PTSS on the right (dark gray bar). Each row represents an X chromosome 
mRNA (with the corresponding official gene symbol to the right) that significantly predicts CMSP/PTSS 
development following MVC. Bolded mRNA represent genes that have been shown previously to escape X 
chromosome inactivation. The dendrogram on the left of the heatmap indicates the hierarchical clustering of X 
chromosome genes associated with CMSP/PTSS.  CMSP = chronic musculoskeletal pain, PTSS = posttraumatic 
stress symptoms. 
 
 
 
 
 
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.  X Chromosome mRNA that predict co-morbid CMSP/PTSS in 
women six months following motor vehicle collision (n=65). 
RNA Fold Differencea β Value 
Std. 
Error 
Z-
score 
p 
Valueb 
SH2D1A 1.58 (655.1/413.7) 1.55 0.49 3.15 0.002 
RPS4X 1.29 (17512.3/13585.3) 1.28 0.41 3.15 0.002 
ELF4 0.82 (4319.1/5236.8) -1.39 0.46 -3.04 0.002 
TCEAL8 1.47 (217.9/147.7) 1.06 0.38 2.75 0.006 
SEPT6 1.18 (12224.9/10333.6) 1.02 0.38 2.72 0.007 
GPR174 1.35 (533.6/394.3) 1.13 0.44 2.59 0.010 
SLC38A5 0.64 (3491.9/5445) -1.03 0.40 -2.57 0.010 
PRPS1 1.18 (554.8/468.2) 0.91 0.35 2.57 0.010 
PRKX 1.14 (2237.1/1954.2) 0.99 0.39 2.56 0.010 
TFE3 0.85 (3400.6/4004.5) -0.91 0.36 -2.52 0.012 
MSN 0.83 (24891.8/30062.4) -0.99 0.40 -2.52 0.012 
WAS 0.8 (9341.2/11624.8) -1.02 0.41 -2.50 0.012 
RPL10 1.27 (22451.2/17620) 0.99 0.40 2.49 0.013 
BEX4 1.33 (304.2/228.9) 0.83 0.34 2.46 0.014 
TAF9B 1.19 (615.4/518.2) 0.85 0.35 2.45 0.014 
RBMX 1.16 (4245.2/3666) 1.05 0.43 2.44 0.015 
CA5B 1.18 (1412.8/1196.6) 0.95 0.39 2.42 0.016 
GPRASP1 1.25 (943.2/755.2) 0.83 0.35 2.35 0.019 
REPS2 0.76 (1989.7/2607.2) -0.75 0.33 -2.31 0.021 
CD40LG 1.15 (1303.5/1132) 0.80 0.35 2.26 0.024 
SPIN2A 0.69 (44.2/64.4) -0.78 0.35 -2.22 0.027 
BEX2 1.49 (120.5/80.6) 0.82 0.37 2.21 0.027 
MPP1 0.79 (7647.5/9736.2) -0.83 0.38 -2.20 0.028 
EIF1AX 1.3 (1458.3/1119.9) 0.88 0.40 2.20 0.028 
TLR8 0.78 (6849.1/8826.4) -0.74 0.34 -2.19 0.028 
VSIG1 1.18 (477.8/403.9) 0.71 0.32 2.19 0.029 
VMA21 1.19 (823.4/694.8) 0.74 0.34 2.18 0.029 
OTUD5 0.91 (2165.2/2378.1) -0.72 0.33 -2.15 0.032 
GPR34 1.28 (240.1/187.2) 0.69 0.32 2.14 0.033 
G6PD 0.85 (3445.5/4054.8) -0.80 0.38 -2.13 0.033 
WDR13 0.89 (803.1/899.7) -0.64 0.30 -2.12 0.034 
SAT1 0.79 (2970.5/3756.3) -0.73 0.35 -2.11 0.035 
RBBP7 1.18 (882.8/745.3) 0.74 0.36 2.09 0.036	
SCML1 1.2 (273.1/227) 0.69 0.33 2.09 0.037	
ITM2A 1.32 (1274/966) 0.90 0.44 2.06 0.039	
UBA1 0.91 (5976.2/6559.7) -0.78 0.38 -2.03 0.042	
WWC3 0.87 (3304.1/3805.4) -0.64 0.32 -2.00 0.045	
EIF2S3 1.11 (5000.1/4511.8) 0.69 0.34 2.00 0.045	
CFP 0.84 (4061.4/4819.9) -0.69 0.34 -1.99 0.046	
NKRF 1.17 (554.5/472.7) 0.64 0.33 1.98 0.048	
aFold difference was calculated by dividing the average sequencing read counts for women who 
developed co-morbid CMSP/PTSS by the average sequencing read counts for women who 
recovered following MVC. bp values were calculated using logistic regression analyses adjusted for 
participant age, enrollment study site, and education level. Bolded mRNA have been defined 
previously as genes that escape X chromosome inactivation. 
B 
C 
D 
Difference in proportions, z-score = -2.9, p = 0.004 
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Test group: CMSP/PTSS associated “EscapeSet” 
Comparison group: Directiond P value 
CMSP/PTSS XCISeta Up 0.0038 
Other XCh genesb Up 8.81E-15 
Other genesc Up 4.75E-12 
Figure 2. In women, gene transcripts previously shown to escape X chromosome inactivation (XCI) are 
important predictors of co-morbid CMSP/PTSS. A) Escape genes are over-represented in the list of 40 X 
chromosome (XCh) genes that significantly predict co-morbid CMSP/PTSS in women following motor 
vehicle collision. The pie chart on the left represents the proportion of all XCh genes that have been shown 
to escape XCI (n=93, yellow wedge) out of the total number of non-PAR XCh genes (n=783); the pie chart 
on the right represents the proportion of genes that have been shown to escape XCI (n=11) out of the total 
number of XCh genes that predict CMSP/PTSS in women following MVC. B) Schematic representation of 
the location of “EscapeSet” genes on the X chromosome. C) Results of competitive gene set analyses 
indicate that EscapeSet genes are more differentially expressed in women who develop co-morbid 
CMSP/PTSS vs recover following MVC than aXChSet genes, bany other set of nine XCh genes, and cany 
other set of nine randomly selected genes from the full transcriptome. dDirection of expression of genes in 
women who developed co-morbid CMSP/PTSS relative to expression of the same genes in women who 
recover following MVC (i.e. “Up” indicates the genes are higher expressed in women with co-morbid 
CMSP/PTSS). D) Network analysis results based on EscapeSet genes using Ingenuity design software 
(IPA, Qiagen). 
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Figure 3.  Relationship between RNA expression levels of key regulators of X Chromosome inactivation, XIST 
and YY1, and posttraumatic stress symptom (PTSS) severity scores in women following MVC trauma.  A) XIST 
RNA expression levels were examined in relation to PTSS severity scores in women who recovered following 
MVC (top left, purple triangles, n=35), and in women who developed co-morbid CMSP/PTSS following MVC (top 
right, teal circles, n=30). YY1 RNA expression levels were also analyzed in relation to PTSS severity scores in 
women who recovered following MVC (bottom left, purple triangles, n=35), and in women who developed co-
morbid CMSP/PTSS following MVC (bottom right, teal circles, n=30). B) The relationship between XIST RNA 
expression levels and YY1 RNA expression levels in women who recovered following MVC (left, green squares, 
n=35) and in women who developed co-morbid CMSP/PTSS following MVC (right, yellow diamonds, n=30). RNA 
expression levels were measured via RNA sequencing of blood collected in the early aftermath of MVC. Bivariate 
analyses were used to derive Pearson correlation coefficients and corresponding p values. 
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Supplementary Table 1. Putative gene functions for XCh mRNA identified as predictors of co-morbid 
CMSP/PTSS in women following motor vehicle collision trauma. 
mRNA Official Gene Name Gene Function 
SH2D1A SH2 domain containing 1A stimulation of the immune system (T and B cells) 
RPS4X ribosomal protein S4, X-linked transcriptional regulation 
ELF4 E74 like ETS transcription factor 4 transcriptional activator, Immune system 
TCEAL8 transcription elongation factor A like 8 transcriptional regulation 
SEPT6 septin 6 GTPase required for cytokinesis 
GPR174 
G protein-coupled receptor 174 
GPCR with unidentified ligand (similar family members 
activate neurotransmitters, hormones) 
SLC38A5 solute carrier family 38 member 5 amino acid transporter 
PRPS1 phosphoribosyl pyrophosphate synthetase 1 enzyme involved in nucleotide synthesis 
PRKX 
protein kinase, X-linked 
serine threonine protein kinase involved in immune cell 
maturation. Also serotonin, adrenergic, dopaminergic, 
GABA, and endogenous opioid pathways. 
TFE3 transcription factor binding to IGHM enhancer 3 transcription factor for genes downstream of TGF-beta 
MSN moesin functions in cell-cell recognition and cell movement 
WAS 
Wiskott-Aldrich syndrome 
transduction of signals from cell surface to actin 
cytoskeleton. Involved in immune regulation and 
microthrombocytopenia 
RPL10 ribosomal protein L10 transcriptional regulation 
BEX4 brain expressed X-linked 4 regulation of transcription 
TAF9B TATA-box binding protein associated factor 9 transcriptional regulation 
RBMX RNA binding motif protein, X-linked 
RNA binding protein involved in the regulation of 
transcription and translation  
CA5B carbonic anhydrase 5B 
mitochondrial carbonic anhydrase involved in wide range 
of biological activities 
GPRASP1 G protein-coupled receptor associated sorting protein 1 
GPCR that interacts with DRD2, OPRD1, ADRB2, DRD4, 
CB1R 
REPS2 RALBP1 associated Eps domain containing 2 
regulates endocytosis and down regulates growth factor 
receptors 
CD40LG CD40 ligand ligand on T cells that regulates B cell function 
SPIN2A spindlin family member 2A 
involved in regulation of cell cycle progression and exhibits 
H3K4me3-binding activity 
BEX2 brain expressed X-linked 2 transcriptional regulation 
MPP1 membrane palmitoylated protein 1 
regulates cell proliferation, signaling pathways, intercellular 
junctions 
EIF1AX eukaryotic translation initiation factor 1A translation initiation 
TLR8 toll like receptor 8 immune system function 
VSIG1 V-set and immunoglobulin domain containing 1 member of the junctional adhesion molecule 
VMA21 vacuolar ATPase assembly factor required for assembly of lysosomal vacuolar ATPase 
OTUD5 OTU deubiquitinase 5 
suppressor of type I interferon-dependent innate immune 
response 
GPR34 G protein-coupled receptor 34 GPCR involved in the immune response 
G6PD glucose-6-phosphate dehydrogenase enzyme involved in NADPH production 
WDR13 WD repeat domain 13 
involved in signal transduction, apoptosis, cell cycle 
progression, gene regulation 
SAT1 spermidine/spermine N1-acetyltransferase 1 enzyme involved in polyamine metabolism 
RBBP7 RB binding protein 7, chromatin remodeling factor cell proliferation and differentiation 
SCML1 Scm polycomb group protein like 1 
helps maintain transcriptionally repressive state of 
homeotic genes throughout development 
ITM2A integral membrane protein 2A potential role in osteo- and chondrogenic differentiation 
UBA1 ubiquitin like modifier activating enzyme 1 DNA repair 
WWC3 WWC family member 3 kinase binding and protein complex scaffold 
EIF2S3 eukaryotic translation initiation factor 2 subunit gamma translation initiation 
CFP complement factor properdin 
positively regulates the alternative complement pathway of 
the innate immune system 
NKRF NFKB repressing factor transcriptional repression of NFKB responsive genes 
	
	
  
	
	 	
Supplementary Figure 1. Heatmap illustrating X chromosome genes that are differentially expressed in 
men who recover vs develop co-morbid CMSP/PTSS six months following motor vehicle collision (MVC) 
(n=36). Each column represents a male participant from the study, with individuals who recovered on the 
left (light gray bar) and individuals who developed CMSP/PTSS on the right (dark gray bar). Each row 
represents an X chromosome mRNA (with the corresponding official gene symbol to the right) that 
significantly predicts CMSP/PTSS development following MVC. Bolded mRNA represents genes that have 
been shown previously to escape X chromosome inactivation. The dendrogram on the left of the heatmap 
indicates the hierarchical clustering of X chromosome genes associated with CMSP/PTSS.  CMSP = chronic 
musculoskeletal pain, PTSS = posttraumatic stress symptoms. 
	
	
	
 
 
	 	
Supplementary Table 2. XCh mRNA that predict co-morbid CMSP/PTSS in 
men six months following motor vehicle collision (n=36). 
RNA	 Fold Differencea β Value 
Std. 
Error 
Z-
score 
p 
Valueb 
TSR2 1.5 (349.9/233.8) 1.59 0.59 2.70 0.007 
USP11 1.25 (870.1/694.1) 1.92 0.71 2.69 0.007 
RNF113A 1.32(408.4/308.7) 1.28 0.50 2.55 0.011 
SMC1A 1.32 (3157.6/2386.2) 1.83 0.74 2.48 0.013 
NONO 1.18 (5181.3/4384.3) 1.56 0.65 2.40 0.017 
FLNA 1.33 (31586.2/23673.7) 1.13 0.49 2.30 0.021 
UPF3B 1.54 (409.5/266.3) 1.33 0.58 2.29 0.022 
SEPT6 1.22 (8523.2/7007.8) 1.30 0.61 2.15 0.032 
TNMD 3.16 (46.2/14.6) 1.81 0.85 2.13 0.033 
IL2RG 1.29 (9020.7/6979.2) 1.79 0.84 2.12 0.034 
RBMX2 1.32 (267.1/202.3) 1.07 0.50 2.12 0.034 
ZRSR2 1.38 (518.9/374.7) 0.99 0.47 2.09 0.036 
FMR1 1.29 (1418.9/1098.2) 0.92 0.44 2.09 0.037 
HTATSF1 1.43 (589.5/413.3) 1.00 0.48 2.08 0.038 
ARHGEF6 1.2 (4523.6/3757.8) 1.05 0.51 2.07 0.038 
TREX2 0.59 (29.6/50.3) -0.99 0.48 -2.07 0.038 
P2RY4 0.58 (33/56.8) -0.91 0.44 -2.06 0.04 
CXorf58 1.86 (33.9/18.2) 1.50 0.73 2.06 0.04 
BCOR 1.22 (2273/1857.9) 1.08 0.53 2.05 0.04 
DIAPH2 1.23 (1392.9/1128.9) 0.92 0.45 2.04 0.041 
HUWE1 1.23 (8522.9/6922.1) 1.07 0.53 2.04 0.042 
RBBP7 1.28 (774.3/603.8) 1.00 0.50 2.02 0.043 
HDAC6 1.2 (1060.4/886.2) 1.01 0.50 2.02 0.044 
ARMCX3 1.23 (401.8/325.4) 0.90 0.45 1.99 0.047 
GAGE1 15.71 (11/0.7) 3.02 1.52 1.98 0.048 
aFold difference was calculated by dividing the average sequencing read counts for 
men who developed co-morbid CMSP/PTSS by the average sequencing read counts 
for men who recovered following MVC. bp values were calculated using logistic 
regression analyses adjusted for participant age, enrollment study site, and education 
level. Bolded mRNA have been defined previously as genes that escape X 
chromosome inactivation.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
Supplementary Table 3.  Genes known to escape X chromosome inactivation as described by 
Carolyn Brown and colleagues (see manuscript for associated reference). 
Escapea 
Mostly 
Escapeb Variable Escapec 
Mostly Variable 
Escape d 
ARSH GYG2 ASB11 KIAA1210 ARSE 
PRKX ARSD BEND2 SH2D1A SHROOM2 
STS MXRA5 PPEF1 FRMD7 GRPR 
PNPLA4 NLGN4X PHEX MGC1612184848 NHS 
FAM9C KAL13730 CXorf21 PLAC1 PABPC5 
ACE2 TCEANC MED14 BRS3 COL4A6 
ZRSR2 RAB9A TIMP1 CD40LG PLS3 
S100G TRAPPC2 WAS MAGEA11 NAA10 
SYAP1 OFD1 DGAT2L6 MAGEA8 HCFC1 
TXLNG GPM6B FOXO4  TMEM187 
EIF1AX GEMIN8 CXorf65   
EIF2S3 CA5B MED149282   
ZFX AP1S2 TSIX   
VENTXP1 CTPS2 COX7B   
CXorf38 RBBP7 P2RY10   
DDX3X USP9X GPR174   
FUNDC1 KDM6A POF1B   
UBA1 CDK16 SRPX2   
INE1 KDM5C NXF3   
TAF7L IQSEC2 WBP551186   
NXF5 SMC1A GLRA4   
ZCCHC16340595 RPS4X GUCY2F   
GPR112139378 NAP1L3 RGAG157529   
VGLL1 HTR2C ALG13   
 L1CAM TRPC5   
agene has been shown to escape from X Chromosome inactivation (XCI) as identified in a wide range of 
studies. bgene has been shown to escape from XCI in the majority of studies (2 of 3 or 3 of 4 reviewed studies). 
cgene has been shown in a wide range of studies to variably escape from XCI in some individuals or tissues. 
dgene has been shown in the majority of studies to variably escape from XCI in some individuals or tissues. 
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Supplementary Figure 2. Relationship between RNA expression levels of key regulators of X 
Chromosome inactivation, XIST and YY1, and chronic musculoskeletal pain (CMSP) severity scores in 
women following MVC trauma.  A) XIST RNA expression levels were examined in relation to CMSP 
severity scores in women who recovered following MVC (top left, purple triangles, n=35), and in women 
who developed co-morbid CMSP/PTSS following MVC (top right, teal circles, n=30). YY1 RNA expression 
levels were also analyzed in relation to CMSP severity scores in women who recovered following MVC 
(bottom left, purple triangles, n=35), and in women who developed co-morbid CMSP/PTSS following MVC 
(bottom right, teal circles, n=30). 
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Supplementary Figure 3.  Relationship between RNA expression levels of key regulators of X 
Chromosome inactivation, XIST and YY1, and posttraumatic stress symptom (PTSS) severity scores in 
men following MVC trauma.  A) XIST RNA expression levels were examined in relation to PTSS severity 
scores in men who recovered following MVC (top left, purple triangles, n=15), and in men who developed 
co-morbid CMSP/PTSS following MVC (top right, teal circles, n=21). YY1 RNA expression levels were also 
analyzed in relation to PTSS severity scores in men who recovered following MVC (bottom left, purple 
triangles, n=15), and in men who developed co-morbid CMSP/PTSS following MVC (bottom right, teal 
circles, n=21). B) The relationship between XIST RNA expression levels and YY1 RNA expression levels 
in men who recovered following MVC (left, green squares, n=15) and in men who developed co-morbid 
CMSP/PTSS following MVC (right, yellow diamonds, n=21). RNA expression levels were measured via 
RNA sequencing of blood collected in the early aftermath of MVC. Bivariate analyses were used to derive 
Pearson correlation coefficients and corresponding p values. 
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Supplementary Figure 4. Relationship between RNA expression levels of key regulators of X 
Chromosome inactivation, XIST and YY1, and chronic musculoskeletal pain (CMSP) severity scores in 
men following MVC trauma.  A) XIST RNA expression levels were examined in relation to CMSP severity 
scores in men who recovered following MVC (top left, purple triangles, n=15), and in men who developed 
co-morbid CMSP/PTSS following MVC (top right, teal circles, n=21). YY1 RNA expression levels were also 
analyzed in relation to CMSP severity scores in men who recovered following MVC (bottom left, purple 
triangles, n=15), and in men who developed co-morbid CMSP/PTSS following MVC (bottom right, teal 
circles, n=21). 
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